Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors

Trial Profile

A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2018

At a glance

  • Drugs Concizumab (Primary) ; Eptacog alfa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Therapeutic Use
  • Acronyms explorer™4
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Sep 2018 Planned End Date changed from 14 Nov 2019 to 31 Jan 2020.
    • 31 Aug 2018 Biomarkers information updated
    • 03 Jul 2018 Planned primary completion date changed from 29 Aug 2018 to 20 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top